Can selinexor be used simultaneously with immunotherapy?

Selinexor () is a selective nuclear export inhibitor mainly used to treat multiple myeloma and certain lymphomas. In recent years, with the development of immunotherapy, many tumor patients have begun to receive immunotherapy such as immune checkpoint inhibitors. Whether selinesol can be used simultaneously with immunotherapy has become a hot issue in clinical practice.

From a mechanism perspective, selinesol inhibits the nuclear export protein XPO1 and blocks the transport of key proteins in tumor cells, thereby inducing cancer cell apoptosis. This mechanism is different from the way immune checkpoint inhibitors act on the immune system, and theoretically the two have the potential to work synergistically. Some studies and clinical trials are exploring the safety and effectiveness of selinesol in combination with immunotherapy, and preliminary data show that combining the two may enhance anti-tumor effects.

However, selinesol itself has obvious side effects, including fatigue, nausea, hematological toxicity, etc. These adverse reactions may be superimposed on the immune-related side effects of immunotherapy, increasing patient discomfort and management difficulty. Therefore, whether to use it simultaneously requires a comprehensive assessment of the patient's overall health status and tolerance and the development of an individualized treatment plan under the guidance of a professional doctor.

In summary, the simultaneous use of selinexole and immunotherapy has certain scientific basis and clinical potential, but there are currently no clear recommendations from extensive clinical guidelines. Patients should closely monitor adverse reactions during treatment and adjust treatment plans in a timely manner. More clinical studies in the future will provide more sufficient evidence to support this combined treatment model.

Reference materials:https://www.selincro.com/